Report cover image

Fibromyalgia Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 151 Pages
SKU # FOB19472364

Description

Fibromyalgia Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Fibromyalgia Treatment Market

The Fibromyalgia Treatment Market size was valued at USD 19.18 billion in 2023, and the market is now projected to grow to 141.4 USD billion by 2032, exhibiting a CAGR of 9.2% during the forecast period of 2023-2030.

As a result of the government's lockdown and other steps to stop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related to this domain. This has affected the overall supply and demand chains of the particular market. The market has suffered because fewer patients are seeking therapy for fibromyalgia as a result of the pandemic, which is detrimental because the condition is a less well-known and underdiagnosed indication. These factors affected the Fibromyalgia Treatment Market Growth.

This is the major factor attributing the growth of this particular market. This factor is majorly involved in taking the revenue numbers above the skies and soaring greater heights and also the sales and demands have been proliferation and increased its value to greater extent.The global fibromyalgia treatment market is growing due to a number of causes. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that fibromyalgia affects about five million people in the United States. These particular growth driving factors have been recorded to attribute the Fibromyalgia Treatment Market share. A lot of growth has been observed in the recent times because of this particular factor that contributed and also acted as a catalyst to the overall development of the product market.

A latest trend has been witnessed to proliferate the market growth. This particular trend has been recorded to be the most profiting trends that have been upgraded to augment the overall market growth. A lot of specifications have been made to this particular product which has benefited the market growth. The market for medications used to treat fibromyalgia is expected to increase significantly in the coming years due to the increasing prevalence of the condition. This specific trend has influenced the market growth so much so that the revenue and share numbers of this particular product is touching the skies and soaring over. The expansion of pre-marketed items in the sector is being actively pursued by key companies that are aware of this market potential. For example, a phase 2 clinical trial for the treatment of fibromyalgia is presently underway for Teva Pharmaceuticals' AJOVY, which is already approved in the United States for migraine. It is anticipated that this crucial trend would favorably impact market expansion throughout the course of the projection year.

Comprehensive Analysis of Fibromyalgia Treatment Market

The segmentation of this particular market has been divided and then further subdivided into various categories. Drug class divides the market into muscle relaxants, antidepressants, antiepileptics, and others (including pipeline items). Hospital pharmacies, retail pharmacies, and online pharmacies are all part of the fibromyalgia therapy market, according to the distribution channel segmentation.

This particular region has augmented a lot in the past few years in this particular product market. This specific region held the biggest revenue share. Some of the major Companies includes Numerous factors, including the growing incidence of fibromyalgia, are propelling the market expansion in Europe. Additionally, it is anticipated that the dearth of fibromyalgia treatment alternatives and prospective product introductions will support market expansion in the upcoming years. In addition, it is expected that the European Commission's increase in healthcare funding will support the region's expansion. This particular region has experienced immense proliferation in the market shares and has attributed to the global market revenue.

Global markets are fiercely competitive and highly fragmented. Due to their creative packaging solutions, a few group of large market companies hold a fair amount of market share. Some of the major Companies includes Pfizer, Inc.(U.S.), Eli Lilly and Company (U.S.), Allergan (Ireland), Tonix Pharmaceuticals (U.S.), and Aptinyx (U.S.).

In December 2020, This particular company has attributed the market growth in terms of revenue and shares system. According to Tonix Pharmaceutical, the company's TNX-102 phase 3 research results for the treatment of fibromyalgia were positive. This particular development and investment the global market has been recorded to be a boon for the market growth.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD Million)

Segmentation Drug Class, Distribution Channel, and Region

By Drug Class

Antidepressants

Antiepileptic

Muscle Relaxants

Others (incl. Pipeline Products)

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America

By Drug Class

By Distribution Channel

By Country

USA (By Drug Class)

Canada (By Drug Class)

Europe

By Drug Class

By Distribution Channel

By Country

UK (By Drug Class)

Germany (By Drug Class)

France (By Drug Class)

Italy (By Drug Class)

Spain (By Drug Class)

Scandinavia (By Drug Class)

Rest of Europe (By Drug Class)

Asia Pacific

By Drug Class

By Distribution Channel

By Country

Japan (By Drug Class)

China (By Drug Class)

India (By Drug Class)

Australia (By Drug Class)

Southeast Asia (By Drug Class)

Rest of Asia Pacific (By Drug Class)

Latin America

By Drug Class

By Distribution Channel

By Country

Brazil (By Drug Class)

Mexico (By Drug Class)

Rest of Latin America (By Drug Class)

Middle East & Africa

By Drug Class

By Distribution Channel

By Country

GCC (By Drug Class)

South Africa (By Drug Class)

Rest of MEA (By Drug Class)

Table of Contents

151 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Fibromyalgia by key Regions
4.2. Key Industry Trends
4.3. Pipeline Analysis
4.4. Regulatory Scenario
4.5. Recent Industry Developments Such as Mergers & Acquisitions
4.6. Impact of COVID-19 on the Market
5. Global Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Antidepressants
5.2.2. Antiepileptic
5.2.3. Muscle Relaxants
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacy
5.3.2. Retail Pharmacy
5.3.3. Online Pharmacy
5.4. Market Analysis, Insights and Forecast – By Country
5.4.1. North America
5.4.2. Europe
5.4.3. Asia pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Antidepressants
6.2.2. Antiepileptic
6.2.3. Muscle Relaxants
6.2.4. Others
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.1.1. By Drug Class
6.4.1.1.1. Antidepressants
6.4.1.1.2. Antiepileptic
6.4.1.1.3. Muscle Relaxants
6.4.1.1.4. Others
6.4.2. Canada
6.4.2.1. By Drug Class
6.4.2.1.1. Antidepressants
6.4.2.1.2. Antiepileptic
6.4.2.1.3. Muscle Relaxants
6.4.2.1.4. Others
7. Europe Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Class
7.2.1. Antidepressants
7.2.2. Antiepileptic
7.2.3. Muscle Relaxants
7.2.4. Others
7.3. Market Analysis – By Distribution Channel
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Market Analysis – By Country
7.4.1. U.K.
7.4.1.1. By Drug Class
7.4.1.1.1. Antidepressants
7.4.1.1.2. Antiepileptic
7.4.1.1.3. Muscle Relaxants
7.4.1.1.4. Others
7.4.2. Germany
7.4.2.1. By Drug Class
7.4.2.1.1. Antidepressants
7.4.2.1.2. Antiepileptic
7.4.2.1.3. Muscle Relaxants
7.4.2.1.4. Others
7.4.3. France
7.4.3.1. By Drug Class
7.4.3.1.1. Antidepressants
7.4.3.1.2. Antiepileptic
7.4.3.1.3. Muscle Relaxants
7.4.3.1.4. Others
7.4.4. Spain
7.4.4.1. By Drug Class
7.4.4.1.1. Antidepressants
7.4.4.1.2. Antiepileptic
7.4.4.1.3. Muscle Relaxants
7.4.4.1.4. Others
7.4.5. Italy
7.4.5.1. By Drug Class
7.4.5.1.1. Antidepressants
7.4.5.1.2. Antiepileptic
7.4.5.1.3. Muscle Relaxants
7.4.5.1.4. Others
7.4.6. Scandinavia
7.4.6.1. By Drug Class
7.4.6.1.1. Antidepressants
7.4.6.1.2. Antiepileptic
7.4.6.1.3. Muscle Relaxants
7.4.6.1.4. Others
7.4.7. Rest of Europe
7.4.7.1. By Drug Class
7.4.7.1.1. Antidepressants
7.4.7.1.2. Antiepileptic
7.4.7.1.3. Muscle Relaxants
7.4.7.1.4. Others
8. Asia Pacific Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Class
8.2.1. Antidepressants
8.2.2. Antiepileptic
8.2.3. Muscle Relaxants
8.2.4. Others
8.3. Market Analysis – By Distribution Channel
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Analysis – By Country
8.4.1. Japan
8.4.1.1. By Drug Class
8.4.1.1.1. Antidepressants
8.4.1.1.2. Antiepileptic
8.4.1.1.3. Muscle Relaxants
8.4.1.1.4. Others
8.4.2. China
8.4.2.1. By Drug Class
8.4.2.1.1. Antidepressants
8.4.2.1.2. Antiepileptic
8.4.2.1.3. Muscle Relaxants
8.4.2.1.4. Others
8.4.3. India
8.4.3.1. By Drug Class
8.4.3.1.1. Antidepressants
8.4.3.1.2. Antiepileptic
8.4.3.1.3. Muscle Relaxants
8.4.3.1.4. Others
8.4.4. Australia
8.4.4.1. By Drug Class
8.4.4.1.1. Antidepressants
8.4.4.1.2. Antiepileptic
8.4.4.1.3. Muscle Relaxants
8.4.4.1.4. Others
8.4.5. Southeast Asia
8.4.5.1. By Drug Class
8.4.5.1.1. Antidepressants
8.4.5.1.2. Antiepileptic
8.4.5.1.3. Muscle Relaxants
8.4.5.1.4. Others
8.4.6. Rest of Asia Pacific
8.4.6.1. By Drug Class
8.4.6.1.1. Antidepressants
8.4.6.1.2. Antiepileptic
8.4.6.1.3. Muscle Relaxants
8.4.6.1.4. Others
9. Latin America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Class
9.2.1. Antidepressants
9.2.2. Antiepileptic
9.2.3. Muscle Relaxants
9.2.4. Others
9.3. Market Analysis – By Distribution Channel
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Analysis – By Country
9.4.1. Brazil
9.4.1.1. By Drug Class
9.4.1.1.1. Antidepressants
9.4.1.1.2. Antiepileptic
9.4.1.1.3. Muscle Relaxants
9.4.1.1.4. Others
9.4.2. Mexico
9.4.2.1. By Drug Class
9.4.2.1.1. Antidepressants
9.4.2.1.2. Antiepileptic
9.4.2.1.3. Muscle Relaxants
9.4.2.1.4. Others
9.4.3. Rest of Latin America
9.4.3.1. By Drug Class
9.4.3.1.1. Antidepressants
9.4.3.1.2. Antiepileptic
9.4.3.1.3. Muscle Relaxants
9.4.3.1.4. Others
10. Middle East & Africa Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Drug Class
10.2.1. Antidepressants
10.2.2. Antiepileptic
10.2.3. Muscle Relaxants
10.2.4. Others
10.3. Market Analysis – By Distribution Channel
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Analysis – By Country
10.4.1. GCC
10.4.1.1. By Drug Class
10.4.1.1.1. Antidepressants
10.4.1.1.2. Antiepileptic
10.4.1.1.3. Muscle Relaxants
10.4.1.1.4. Others
10.4.2. South Africa
10.4.2.1. By Drug Class
10.4.2.1.1. Antidepressants
10.4.2.1.2. Antiepileptic
10.4.2.1.3. Muscle Relaxants
10.4.2.1.4. Others
10.4.3. Rest of Middle East & Africa
10.4.3.1. By Drug Class
10.4.3.1.1. Antidepressants
10.4.3.1.2. Antiepileptic
10.4.3.1.3. Muscle Relaxants
10.4.3.1.4. Others
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. Pfizer, Inc.
11.5.1.1. Overview,
11.5.1.2. Products & services,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. strategies,
11.5.1.6. financials (based on availability)
11.5.2. Eli Lilly and Company
11.5.2.1. Overview,
11.5.2.2. Products & services,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. strategies,
11.5.2.6. financials (based on availability)
11.5.3. Allegran
11.5.3.1. Overview,
11.5.3.2. Products & services,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. strategies,
11.5.3.6. financials (based on availability)
11.5.4. Tonix Pharmaceuticals
11.5.4.1. Overview,
11.5.4.2. Products & services,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. strategies,
11.5.4.6. financials (based on availability)
11.5.5. Aptinyx
11.5.5.1. Overview,
11.5.5.2. Products & services,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. strategies,
11.5.5.6. financials (based on availability)
11.5.6. Teva Pharmaceutical Industries Ltd.
11.5.6.1. Overview,
11.5.6.2. Products & services,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. strategies,
11.5.6.6. financials (based on availability)
11.5.7. Novartis AG
11.5.7.1. Overview,
11.5.7.2. Products & services,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. strategies,
11.5.7.6. financials (based on availability)
11.5.8. Sun Pharmaceuticals
11.5.8.1. Overview,
11.5.8.2. Products & services,
11.5.8.3. SWOT analysis,
11.5.8.4. Recent developments,
11.5.8.5. strategies,
11.5.8.6. financials (based on availability)
11.5.9. Astella Pharma Inc
11.5.9.1. Overview,
11.5.9.2. Products & services,
11.5.9.3. SWOT analysis,
11.5.9.4. Recent developments,
11.5.9.5. strategies,
11.5.9.6. financials (based on availability)
11.5.10. Other Prominent Players
11.5.10.1. Overview,
11.5.10.2. Products & services,
11.5.10.3. SWOT analysis,
11.5.10.4. Recent developments,
11.5.10.5. strategies,
11.5.10.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us